Blood Sugar & Diabetes Risk
Last reviewed: May 2026
The A1C test is the primary tool doctors use to evaluate long-term blood sugar control and diagnose diabetes. Unlike a fasting glucose test (which captures a single moment), A1C provides a rolling 2-3 month average by measuring how much glucose has bonded to your hemoglobin.[1] This makes it harder to game with short-term dietary changes and gives a more honest picture of glucose management. Regular A1C monitoring is critical because every 1% reduction in A1C is associated with roughly 21% reduction in diabetes-related deaths and 37% reduction in microvascular complications.[2]
| A1C (%) | eAG (mg/dL) | Category | Action |
|---|---|---|---|
| Below 5.7% | <117 | Normal | Rescreen every 3 years if over 45 |
| 5.7–6.4% | 117–137 | Prediabetes | Lifestyle changes; retest annually |
| 6.5–7.0% | 140–154 | Diabetes (controlled) | Continue therapy; test every 3–6 months |
| 7.1–8.0% | 157–183 | Diabetes (above target) | Adjust medication; test quarterly |
| Above 8.0% | >183 | Diabetes (high risk) | Urgent medication review |
The A1C test (also called hemoglobin A1C or HbA1c) measures the percentage of hemoglobin proteins in your red blood cells that have glucose attached to them — a process called glycation. Because red blood cells live approximately 120 days, the A1C reflects your average blood sugar level over the past 2–3 months, with the most recent 30 days weighted most heavily. Unlike a fasting glucose test that captures a single moment, A1C provides a comprehensive picture of blood sugar control over time, making it the primary diagnostic and monitoring tool for diabetes.
| A1C (%) | Estimated Avg Glucose (mg/dL) | Classification |
|---|---|---|
| 4.0% | 68 | Normal |
| 5.0% | 97 | Normal |
| 5.7% | 117 | Prediabetes threshold |
| 6.0% | 126 | Prediabetes |
| 6.5% | 140 | Diabetes threshold |
| 7.0% | 154 | Common treatment target |
| 8.0% | 183 | Above target — increased risk |
| 9.0% | 212 | High — significant complication risk |
| 10.0% | 240 | Very high — urgent attention needed |
The American Diabetes Association uses A1C as a primary diagnostic criterion. An A1C below 5.7% is considered normal, 5.7–6.4% indicates prediabetes, and 6.5% or above on two separate tests confirms diabetes. Approximately 96 million American adults — 1 in 3 — have prediabetes, and 80% of them do not know it. Prediabetes is reversible with lifestyle changes: a landmark study (the Diabetes Prevention Program) showed that moderate weight loss of 5–7% of body weight combined with 150 minutes of weekly physical activity reduced the progression from prediabetes to Type 2 diabetes by 58%. For adults over 60, the risk reduction was even higher at 71%.
The standard treatment target for most adults with diabetes is an A1C below 7%, which has been shown to significantly reduce the risk of microvascular complications — eye disease (retinopathy), kidney disease (nephropathy), and nerve damage (neuropathy). Each 1% reduction in A1C decreases microvascular complication risk by approximately 37% and diabetes-related death by 21%. However, targets are individualized. Younger patients with recently diagnosed diabetes and no complications may aim for 6.0–6.5%. Older patients, those with long-standing diabetes, or those at high risk for hypoglycemia may have a relaxed target of 7.5–8.0% to avoid dangerous low blood sugar episodes.
Several conditions can cause A1C results to be falsely high or low, independent of actual blood sugar control. Iron deficiency anemia, vitamin B12 deficiency, and chronic kidney disease can falsely elevate A1C. Recent blood loss, blood transfusions, erythropoietin therapy, and hemolytic anemias can falsely lower it. Hemoglobin variants common in certain populations (sickle cell trait, hemoglobin C, hemoglobin E) can interfere with some A1C testing methods, producing inaccurate results. If your A1C seems inconsistent with your day-to-day glucose readings, discuss these potential interfering factors with your physician — an alternative metric like fructosamine or glycated albumin may be more appropriate.
The estimated average glucose (eAG) formula is: eAG (mg/dL) = (28.7 × A1C) − 46.7. This conversion allows patients to relate their A1C result to the numbers they see on their glucose meter throughout the day. An A1C of 7% corresponds to an average glucose of approximately 154 mg/dL. Understanding this translation helps bridge the gap between the quarterly lab result and daily glucose monitoring, making A1C feel less abstract and more connected to everyday management decisions.
Diet and exercise can reduce A1C by 0.5–2.0% depending on starting level and intervention intensity. The most effective dietary approaches include reducing refined carbohydrate and added sugar intake, increasing fiber consumption to 25–30 grams per day, controlling portion sizes, and distributing carbohydrates evenly across meals rather than consuming large carbohydrate loads at once. Exercise improves insulin sensitivity for 24–72 hours after each session — regular physical activity (30 minutes of moderate exercise 5 days per week) can lower A1C by 0.5–0.7% independent of weight loss. Combining dietary changes with exercise typically produces additive benefits.
The relationship between A1C and diabetic complications is well-established through landmark studies. The DCCT trial for Type 1 and the UKPDS trial for Type 2 diabetes both demonstrated that intensive blood sugar control significantly reduces complication rates. Retinopathy risk increases sharply above A1C 7%, with each 1% increase above 7% roughly doubling the risk of progression. Kidney disease and nerve damage follow similar patterns. Cardiovascular risk also increases with higher A1C, though the relationship is more complex and influenced by other factors like blood pressure, cholesterol, and smoking status.
The ADA recommends A1C testing at least twice per year for people with stable diabetes meeting treatment goals, and quarterly for those whose therapy has changed or who are not meeting targets. For people with prediabetes, annual testing monitors for progression. The test requires a standard blood draw or can be performed with a point-of-care device in the physician's office providing results in minutes. Home A1C test kits are available for between-visit monitoring, though their accuracy is somewhat lower than laboratory assays. Continuous glucose monitors (CGMs) now report a "GMI" (Glucose Management Indicator) that closely approximates A1C from sensor data, providing real-time trend information between formal lab tests.
When lifestyle changes alone are insufficient, several medication classes lower A1C effectively. Metformin remains the first-line treatment, typically reducing A1C by 1.0–1.5%. GLP-1 receptor agonists (semaglutide, liraglutide) lower A1C by 1.0–1.8% while also promoting weight loss of 5–15%. SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce A1C by 0.5–1.0% and provide cardiovascular and kidney protection. Insulin therapy can lower A1C by 1.5–3.5% but carries risks of hypoglycemia and weight gain. Treatment selection is increasingly personalized based on cardiovascular risk, kidney function, weight considerations, cost, and patient preference — the era of one-size-fits-all diabetes management has given way to individualized therapy guided by the specific characteristics of each patient.
→ Track trends over time. A single test matters less than the trajectory over 6-12 months.[1]
→ Test at the right time. Results can lag 2-3 weeks behind recent glucose changes.
→ Pair with daily monitoring. A1C does not capture glucose variability within the day.[2]
→ Discuss targets with your doctor. Individual A1C goals vary based on age, complications, and hypoglycemia risk.
See also: Blood Pressure · BMI · Calorie Calculator · Macro Calculator